https://www.selleckchem.com/pr....oducts/phosphoramido
Identification of clinical predictors of response to first-line therapies for EoE is needed to guide initial medical management. A retrospective analysis of patients diagnosed with EoE from 2011 to 2018 was conducted. Clinical and diagnostic variables including demographics, endoscopic, and esophagram findings were compared between PPI responders and PPI nonresponders. All patients underwent a standard 8-week twice-daily PPI trial, with PPI responsiveness defined as 15 eos/hpf on repeat EGD. Univariate and mult
Like
Comment
Share
